Vincenzina Rubino

Dr. Vincenzina Rubino

orcid

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 April 2026 in Clinical and Experimental Dermatology
Verified
Journal Article
Closed access
VRVincenzina Rubino
Vincenzina Rubino
MBmaria efenesia baffa
maria efenesia baffa
SVSasha Visinoni
Sasha Visinoni
SCStefano Colabrese
Stefano Colabrese
LNLuca Novelli
Luca Novelli
EAEmiliano Antiga
Emiliano Antiga
Scleromyxoedema is a rare primary cutaneous mucinosis characterized by a generalized papular and sclerodermoid eruption and typically associated with monoclonal gammopathy. We report an 81-year-old man with Waldenström macroglobulinemia on zanobrutinib who presented with rapidly progressive upper-limb edema, waxy papules, and skin thickening. Histopathology showed diffuse dermal mucin deposition with fibroblast proliferation and fibrosis, consistent with scleromyxoedema. Therapeutic plasma exchange led to partial cutaneous improvement, but the patient subsequently developed fatal intestinal ischemia. This case highlights the characteristic features and potential severity of scleromyxoedema and contributes to the limited literature on therapeutic plasma exchange in this condition.

28 August 2026 in Contact Dermatitis
Verified
Journal Article
Closed access
VRVincenzina Rubino
Vincenzina Rubino
DCDebora Carpentieri
Debora Carpentieri
GMGiulio Montesi
Giulio Montesi
FBFrancesco Borzacchiello
Francesco Borzacchiello
ISImma Savarese
Imma Savarese
NMNicola Milanesi
Nicola Milanesi

31 July 2026 in Dermatology Practical & Conceptual
Verified
Journal Article
Open access
PDF file
VRVincenzina Rubino
Vincenzina Rubino
EDElisa Margherita Difonzo
Elisa Margherita Difonzo
LPLuigi Pisano
Luigi Pisano

Verified
Journal Article
Open access
PDF file
MBmaria efenesia baffa
maria efenesia baffa
RMRoberto Maglie
Roberto Maglie
SCStefano Colabrese
Stefano Colabrese
CPCarlo Pipitò
Carlo Pipitò
VRVincenzina Rubino
Vincenzina Rubino
EAEmiliano Antiga
Emiliano Antiga
Vitiligo is an autoimmune depigmenting disorder characterized by marked heterogeneity in therapeutic response, both between patients and among lesions within the same individual. While current therapies primarily target interferon-γ (IFN-γ)-driven inflammation, clinical outcomes remain variable and frequently incomplete, suggesting that additional lesion-specific biological factors contribute to repigmentation potential. In this narrative review, we propose the concept of repigmentation competence to describe the capacity of an individual lesion to achieve clinically meaningful repigmentation under therapy. We hypothesize that this competence emerges from the interaction of four interconnected biological axes: (i) cytokine network and immune memory, (ii) local immune regulation, (iii) regenerative capacity, and (iv) microenvironmental permissiveness. A targeted search of PubMed/MEDLINE and ClinicalTrials.gov up to March 2026 was conducted to identify translational studies, mechanistic models, and clinical trials relevant to these pathways. Evidence was synthesized thematically with emphasis on cytokine-mediated mechanisms and their interaction with regenerative and tissue-context processes. The IFN-γ/CXCL9/CXCL10 axis and tissue-resident memory T cells (TRM) represent the most clinically validated drivers of disease persistence, as demonstrated by the therapeutic efficacy of JAK inhibitors, although immune suppression alone often fails to achieve complete or durable repigmentation. In contrast, regulatory pathways involving PD-1/PD-L1 signaling, regulatory T cells (Tregs), IL-10, TGF-β, and IL-2–based strategies remain biologically compelling but only partially translated into effective therapies. Regenerative capacity has also emerged as an important determinant of treatment response, with growing evidence supporting the role of melanocyte stem cell niches, follicular regeneration, and Wnt/β-catenin signaling. Accordingly, regenerative approaches such as non-cultured epidermal cell suspension (NCES) are increasingly being integrated into combination therapeutic strategies. The lesional microenvironment remains the least therapeutically developed axis despite growing experimental evidence supporting its importance in melanocyte survival and migration. Collectively, these observations suggest that the variable efficacy of current therapies may reflect different combinations of lesion-specific biological constraints. The emerging benefit of combination strategies may therefore derive not simply from additive effects, but from the simultaneous engagement of multiple axes involved in repigmentation competence. Our review supports a shift from a predominantly drug-centered model toward a lesion-oriented framework integrating immune, regenerative, regulatory, and microenvironmental determinants of response.

1 October 2025 in Skin Health and Disease
Verified
Journal Article
Open access
VRVincenzina Rubino
Vincenzina Rubino
MBmaria efenesia baffa
maria efenesia baffa
CPCarlo Pipitò
Carlo Pipitò
SSSamuele Savian
Samuele Savian
SSStefano Senatore
Stefano Senatore
EAEmiliano Antiga
Emiliano Antiga
In our clinical case, the patient, affected by morphea, reported an excellent response to the administration of baricitinib 4 mg day–1, with rapid disappearance of itching and reduction of the erythematous-infiltrative component of the plaques, highlighting the important role of the JAK/STAT pathway in TGF-β-mediated profibrotic signalling.